Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold

Key Points

• Wall Street Zen downgraded Niagen Bioscience (NASDAQ:NAGE) from a "buy" to a "hold"; overall analyst coverage shows three buys and one hold with a consensus rating of "Moderate Buy" and a consensus price target of $16.
• Shares opened at $4.93 on Friday (up about 4.2%), the company has a market cap of roughly $394.8 million and a P/E of 24.65, with a 12‑month range of $4.16 to $14.69 and 50‑/200‑day moving averages of $4.78 and $5.97.
• Institutional investors recently added new positions and institutions/hedge funds own about 15.41% of the stock; Niagen Bioscience develops and commercializes NAD+ precursor ingredients, including its flagship Niagen (nicotinamide riboside).

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group restated a "buy" rating and issued a $13.00 price objective on shares of Niagen Bioscience in a report on Tuesday, March 31st. Weiss Ratings reiterated a "hold (c)" rating on shares of Niagen Bioscience in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Niagen Bioscience Stock Up 4.2%

NAGE opened at $4.93 on Friday. The company has a market capitalization of $394.79 million, a price-to-earnings ratio of 24.65 and a beta of 2.23. The firm has a 50-day moving average price of $4.78 and a 200-day moving average price of $5.97. Niagen Bioscience has a twelve month low of $4.16 and a twelve month high of $14.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NAGE. CWM LLC purchased a new position in shares of Niagen Bioscience in the third quarter valued at $246,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience in the third quarter valued at $144,000. Financial Consulate Inc. bought a new stake in Niagen Bioscience in the third quarter worth $33,000. D.A. Davidson & CO. bought a new stake in Niagen Bioscience in the third quarter worth $251,000. Finally, North Star Investment Management Corp. bought a new stake in Niagen Bioscience in the third quarter worth $47,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.